Rapid Micro Biosystems will announce Q2 2025 financial results on August 12, followed by a webcast conference call.
Quiver AI Summary
Rapid Micro Biosystems, Inc. will announce its second quarter 2025 financial results on August 12, 2025, before the market opens, followed by a webcast conference call at 8:30 a.m. ET on the same day. The company, which specializes in automation solutions for the healthcare manufacturing sector, aims to enhance the efficiency and safety of product releases, including biologics and vaccines. Its flagship product, the Growth Direct system, modernizes microbial quality control testing by integrating it into manufacturing, thereby improving accuracy, operational efficiency, and compliance with regulations. Rapid Micro Biosystems is based in Lexington, Massachusetts, with additional manufacturing and operational sites in Lowell, Massachusetts, Switzerland, Germany, and the Netherlands.
Potential Positives
- Rapid Micro Biosystems is set to announce its second quarter 2025 financial results, indicating ongoing business operations and engagement with investors.
- The company's management will host a webcast conference call, providing an opportunity for direct communication with stakeholders and enhancing transparency.
- The announcement highlights the significance of the company's flagship Growth Direct system, which modernizes microbial quality control processes, potentially leading to increased demand from pharmaceutical manufacturers.
- The global presence of Rapid Micro Biosystems, with locations in multiple countries, underscores its operational scale and commitment to addressing worldwide healthcare needs.
Potential Negatives
- Announcement of second quarter financial results may imply potential concerns about the company's performance, as they have not yet provided any financial context or predictions for future quarters.
- The timing of the financial release right before the market opens could signal that the company anticipates volatility, which may lead to investor uncertainty.
- The lack of details regarding financial health or specific challenges faced in the press release raises concerns about transparency and could affect investor confidence.
FAQ
When will Rapid Micro Biosystems release its financial results?
Rapid Micro Biosystems will release its second quarter 2025 financial results on August 12, 2025, before the market opens.
What time is the webcast conference call?
The webcast conference call hosted by Rapid Micro Biosystems will begin at 8:30 a.m. ET on August 12, 2025.
How can I access the webcast?
The live audio webcast can be accessed on the Company’s website through a provided link in the press release.
What is the Growth Direct system?
The Growth Direct system is an automated solution that improves microbial quality control testing in pharmaceutical manufacturing.
Where is Rapid Micro Biosystems headquartered?
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with additional locations in Lowell, Switzerland, Germany, and the Netherlands.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPID Insider Trading Activity
$RPID insiders have traded $RPID stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RPID stock by insiders over the last 6 months:
- ROBERT G. JR. SPIGNESI (PRESIDENT AND CEO) has made 0 purchases and 5 sales selling 57,443 shares for an estimated $195,955.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPID Hedge Fund Activity
We have seen 17 institutional investors add shares of $RPID stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHONFELD STRATEGIC ADVISORS LLC added 1,028,805 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,716,045
- ABG-WTT GLOBAL LIFE SCIENCE CAPITAL PARTNERS GP LTD added 810,000 shares (+78.0%) to their portfolio in Q1 2025, for an estimated $2,138,400
- PARKMAN HEALTHCARE PARTNERS LLC added 735,621 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,942,039
- VANGUARD GROUP INC added 169,145 shares (+23.5%) to their portfolio in Q1 2025, for an estimated $446,542
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 158,542 shares (+inf%) to their portfolio in Q1 2025, for an estimated $418,550
- OMERS ADMINISTRATION CORP added 109,400 shares (+inf%) to their portfolio in Q1 2025, for an estimated $288,816
- EVERNEST FINANCIAL ADVISORS, LLC removed 87,265 shares (-66.5%) from their portfolio in Q2 2025, for an estimated $301,064
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RPID Analyst Ratings
Wall Street analysts have issued reports on $RPID in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 07/28/2025
- Keybanc issued a "Overweight" rating on 02/12/2025
To track analyst ratings and price targets for $RPID, check out Quiver Quantitative's $RPID forecast page.
$RPID Price Targets
Multiple analysts have issued price targets for $RPID recently. We have seen 2 analysts offer price targets for $RPID in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Thomas Flaten from Lake Street set a target price of $8.0 on 07/28/2025
- Paul Knight from Keybanc set a target price of $8.0 on 02/12/2025
Full Release
LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link . The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn .
